Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)

US7629334B1 · kind B1 · utility

Assignee

• Bayer Schering Pharma AG · DE

Inventors

• Kristof Chwalisz · Berlin, DE
• Walter Elger · Berlin, DE
• Gerd Schubert · Jena, DE

Key dates

• Filing date: Aug 31, 2000
• Grant date: Dec 8, 2009
• Expiry date: Dec 12, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/56
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as components for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods of treating hormone deficiency and hormone irregularity symptoms. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred herein.